Weizhi Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Weizhi Chen has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Jiangpeng Wei
Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The First Affiliated Hospital of Fourth Military Medical University (Xijing Hospital), Fourth Military Medical University, Xi'an, China
2 shared publications - Li-Di Xu
Genecast Biotechnol Co Ltd, Wuxi, Peoples R China
2 shared publications - Liang Xia
Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University , Chengdu
2 shared publications - Lunxu Liu
Department of Thoracic Surgery and Institute of Thoracic Oncology West China Hospital, Sichuan University Chengdu China
2 shared publications - Ning Shen
Genecast Biotechnology Co, Ltd, Wuxi, Jiangsu, China
2 shared publications - Rui Qi Gao
Xijing Hospital
2 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9561
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer
Molecular residual disease (MRD), detected through circulating tumor DNA, has emerged as a promising biomarker for surveillance in patients with early-stage non-small cell lung cancer (NSCLC) following curative-intent resection. Here we report the MRD analysis from the phase 3 EVIDENCE trial, which includes patients with stage II–IIIA resected EGFR-mutated NSCLC who have received either adjuvant icotinib or chemotherapy. A total of 1,352 plasma samples from 175 patients are analyzed using the MinerVa Prime assay, a personalized tumor-informed MRD platform. At the landmark timepoint, MinerVa Prime detects MRD positivity in 35.8% (38/106) of patients with stage III disease and 14.7% (10/68) of patients with stage II disease, with a longitudinal positivity rate of 47.4%. MRD-positive status is significantly correlated with inferior disease-free survival (DFS), both at landmark (hazard ratio [HR]: 4.44, P < 0.001) and during longitudinal monitoring (HR: 7.82, P < 0.001). Icotinib confers DFS benefits over chemotherapy in both MRD subgroups, enhancing MRD clearance in MRD-positive patients while reducing molecular recurrence in landmark MRD-negative patients. Longitudinal MRD shows a 91.3% negative predictive value, with a median lead time of 169 days prior to clinical recurrence. Among serial monitoring timepoints, MRD status at 24 weeks post-randomization demonstrates the highest prognostic value.
- 10 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9561
Open AccessClinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer
Molecular residual disease (MRD), detected through circulating tumor DNA, has emerged as a promising biomarker for surveillance in patients with early-stage non-small cell lung cancer (NSCLC) following curative-intent resection. Here we report the MRD analysis from the phase 3 EVIDENCE trial, which includes patients with stage II–IIIA resected EGFR-mutated NSCLC who have received either adjuvant icotinib or chemotherapy. A total of 1,352 plasma samples from 175 patients are analyzed using the MinerVa Prime assay, a personalized tumor-informed MRD platform. At the landmark timepoint, MinerVa Prime detects MRD positivity in 35.8% (38/106) of patients with stage III disease and 14.7% (10/68) of patients with stage II disease, with a longitudinal positivity rate of 47.4%. MRD-positive status is significantly correlated with inferior disease-free survival (DFS), both at landmark (hazard ratio [HR]: 4.44, P < 0.001) and during longitudinal monitoring (HR: 7.82, P < 0.001). Icotinib confers DFS benefits over chemotherapy in both MRD subgroups, enhancing MRD clearance in MRD-positive patients while reducing molecular recurrence in landmark MRD-negative patients. Longitudinal MRD shows a 91.3% negative predictive value, with a median lead time of 169 days prior to clinical recurrence. Among serial monitoring timepoints, MRD status at 24 weeks post-randomization demonstrates the highest prognostic value.
- 25 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (7) , 1474-1484
Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)
Background: Circulating tumor DNA (ctDNA) is valuable for detecting minimal residual disease (MRD). However, studies involving long-term blood sampling are required to comprehensively interpret the clinical use of ctDNA analyses. Methods: We conducted a prospective multicenter cohort study (LUNGCA) for dynamic ctDNA monitoring in lung cancer patients receiving curative-intent surgery. ctDNA analysis was conducted on preoperative plasma samples, at postoperative 3 days and 1 month, and then every 3-6 months for up to 3 years. Results: In total, 233 non-small cell lung cancer (NSCLC) patients and 2336 longitudinal plasma samples were included; the median follow-up was 51.4 months. Post-comprehensive treatment (after radical surgery + necessary adjuvant therapy) MRD status was better at predicting relapse than postoperative MRD status (positive predictive value: 100% vs 90.0%; negative predictive value: 90.3% vs 90.1%). Patients with positive pre-adjuvant ctDNA and targetable mutations in tumor tissues had improved recurrence-free survival (RFS) with corresponding adjuvant tyrosine kinase inhibitor (TKI) treatment (hazard ratio [HR] = 0.01, P = .005), but adjuvant chemotherapy failed to improve RFS (HR = 0.6, P = .491). Of patients receiving adjuvant therapies, patients with a negative- or positive-negative ctDNA change pattern had favorable and similar RFS (P = .419), whereas patients with a positive- or negative-positive pattern had worse RFS (P < .001). TKI therapy was more effective than chemotherapy in clearing ctDNA. Post-relapse ctDNA negativity was associated with favorable OS (HR = 0.4; P = .029). Conclusions: Comprehensive interpretation of dynamic ctDNA monitoring data can inform precise whole-course postsurgical management of NSCLC patients.
- 25 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (7) , 1474-1484
Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)
Background: Circulating tumor DNA (ctDNA) is valuable for detecting minimal residual disease (MRD). However, studies involving long-term blood sampling are required to comprehensively interpret the clinical use of ctDNA analyses. Methods: We conducted a prospective multicenter cohort study (LUNGCA) for dynamic ctDNA monitoring in lung cancer patients receiving curative-intent surgery. ctDNA analysis was conducted on preoperative plasma samples, at postoperative 3 days and 1 month, and then every 3-6 months for up to 3 years. Results: In total, 233 non-small cell lung cancer (NSCLC) patients and 2336 longitudinal plasma samples were included; the median follow-up was 51.4 months. Post-comprehensive treatment (after radical surgery + necessary adjuvant therapy) MRD status was better at predicting relapse than postoperative MRD status (positive predictive value: 100% vs 90.0%; negative predictive value: 90.3% vs 90.1%). Patients with positive pre-adjuvant ctDNA and targetable mutations in tumor tissues had improved recurrence-free survival (RFS) with corresponding adjuvant tyrosine kinase inhibitor (TKI) treatment (hazard ratio [HR] = 0.01, P = .005), but adjuvant chemotherapy failed to improve RFS (HR = 0.6, P = .491). Of patients receiving adjuvant therapies, patients with a negative- or positive-negative ctDNA change pattern had favorable and similar RFS (P = .419), whereas patients with a positive- or negative-positive pattern had worse RFS (P < .001). TKI therapy was more effective than chemotherapy in clearing ctDNA. Post-relapse ctDNA negativity was associated with favorable OS (HR = 0.4; P = .029). Conclusions: Comprehensive interpretation of dynamic ctDNA monitoring data can inform precise whole-course postsurgical management of NSCLC patients.
- Open Access
- 20 September 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48247
Multidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study
Background: Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. Objective: This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. Methods: This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model Results: Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. Conclusions: This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. Trial Registration: ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910
- 20 September 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48247
Open AccessMultidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study
Background: Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. Objective: This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. Methods: This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model Results: Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. Conclusions: This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. Trial Registration: ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910
- Open Access
- 17 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Multidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study (Preprint)
BACKGROUND Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. OBJECTIVE This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. METHODS This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model RESULTS Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. CONCLUSIONS This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. CLINICALTRIAL ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48247
- 17 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMultidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study (Preprint)
BACKGROUND Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. OBJECTIVE This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. METHODS This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model RESULTS Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. CONCLUSIONS This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. CLINICALTRIAL ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48247
- 14 March 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (6) , 1156
Perioperative ctDNA-Based MRD Detection in NSCLC—Response
We appreciate Yu and colleagues for their interest in our study and we would like to give our reply to their concerns.In LUNGCA-1 study, a total of 330 patients with resected tumor tissues and preoperative blood samples available were included in prognostic analysis, and all but one of these 330 patients had at least one available plasma sample at postoperative 3 days and/or 1 month (1). Thus, preoperative circulating tumor DNA (ctDNA) and postoperative ctDNA-based molecular residual disease (MRD) analysis was done for 330 and 329 patients respectively, as reflected in the number of patients in both Fig. 1 and detailed sample information listed in Supplementary Table S5. LUNGCA-1 study was aimed at evaluating the potential of ctDNA-based MRD during perioperative period for predicting disease relapse and identifying patients who may potentially benefit from adjuvant therapy, and throughout the entire article, there was no mentioning of ctDNA testing after adjuvant therapy.We designed two postoperative blood collection timepoints for ctDNA-based MRD detection. We found that the amount of cell-free DNA increased significantly at 3 days after surgery, and then dropped at postoperative 1 month. ctDNA status at postoperative 3 days was significantly associated with recurrence-free survival (P < 0.001), although with lower prognostic value than ctDNA status at postoperative 1 month (HR: 8.6 vs. 14.3). Among 5 patients whose ctDNA was positive at postoperative 3 days but negative at the other two perioperative timepoints, 4 (80.0%) experienced disease relapse, and the only one who remained disease free had received adjuvant therapy and had a relatively short follow-up (437 days) at the time of data lockdown. Therefore, ctDNA at 3 days after surgery proved to be useful in complementing MRD analysis at postoperative 1 month by increasing detection sensitivity without sacrificing specificity.The current LUNGCA-1 study focused on the association of postoperative MRD detection with disease relapse. The clinical relevance of preoperative ctDNA concentration was not a concern of the published paper and therefore not reported. The criteria for determining ctDNA status had been clearly described in the paragraph “Next-generation sequencing and ctDNA analysis” of the Materials and Methods section, as well as the Supplementary Methods. Disease relapse included locoregional recurrence and distant metastases after surgery, which was determined by radiological methods and/or biopsy.See the original Letter to the Editor, p. 1155W. Chen reports other support from Genecast outside the submitted work. No disclosures were reported by the other authors.
- 14 March 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (6) , 1156
Perioperative ctDNA-Based MRD Detection in NSCLC—Response
We appreciate Yu and colleagues for their interest in our study and we would like to give our reply to their concerns.In LUNGCA-1 study, a total of 330 patients with resected tumor tissues and preoperative blood samples available were included in prognostic analysis, and all but one of these 330 patients had at least one available plasma sample at postoperative 3 days and/or 1 month (1). Thus, preoperative circulating tumor DNA (ctDNA) and postoperative ctDNA-based molecular residual disease (MRD) analysis was done for 330 and 329 patients respectively, as reflected in the number of patients in both Fig. 1 and detailed sample information listed in Supplementary Table S5. LUNGCA-1 study was aimed at evaluating the potential of ctDNA-based MRD during perioperative period for predicting disease relapse and identifying patients who may potentially benefit from adjuvant therapy, and throughout the entire article, there was no mentioning of ctDNA testing after adjuvant therapy.We designed two postoperative blood collection timepoints for ctDNA-based MRD detection. We found that the amount of cell-free DNA increased significantly at 3 days after surgery, and then dropped at postoperative 1 month. ctDNA status at postoperative 3 days was significantly associated with recurrence-free survival (P < 0.001), although with lower prognostic value than ctDNA status at postoperative 1 month (HR: 8.6 vs. 14.3). Among 5 patients whose ctDNA was positive at postoperative 3 days but negative at the other two perioperative timepoints, 4 (80.0%) experienced disease relapse, and the only one who remained disease free had received adjuvant therapy and had a relatively short follow-up (437 days) at the time of data lockdown. Therefore, ctDNA at 3 days after surgery proved to be useful in complementing MRD analysis at postoperative 1 month by increasing detection sensitivity without sacrificing specificity.The current LUNGCA-1 study focused on the association of postoperative MRD detection with disease relapse. The clinical relevance of preoperative ctDNA concentration was not a concern of the published paper and therefore not reported. The criteria for determining ctDNA status had been clearly described in the paragraph “Next-generation sequencing and ctDNA analysis” of the Materials and Methods section, as well as the Supplementary Methods. Disease relapse included locoregional recurrence and distant metastases after surgery, which was determined by radiological methods and/or biopsy.See the original Letter to the Editor, p. 1155W. Chen reports other support from Genecast outside the submitted work. No disclosures were reported by the other authors.
- Open Access
- 21 March 2021
- Published by Springer Nature in Wetlands
- Vol. 41 (4) , 1-16
An Effective Method for Wetland Park Health Assessment: a Case Study of the Guangdong Xinhui National Wetland Park in the Pearl River Delta, China
The Guangdong Xinhui National Wetland Park (GXNWP) in the Pearl River Delta is an important stopover for migratory birds in China and East Asia. Due to high levels of interference, high sensitivity and fragile environmental constraints, an efficient method to assess the health status of wetland parks such as the GXNWP is urgently needed for sustainable development. In this study, we proposed a habitat-landscape-service (HLS) conceptual model that can be used at the site scale to evaluate health status in terms of habitats, landscapes and services by considering the complex ecosystem of wetland parks. This HLS model included 28 evaluation indicators, and the indicator weights and health-grade divisions were based on expert scores using both the analytic hierarchy process (AHP) and fuzzy comprehension evaluation (FCE) methods. The results showed that the health status of the GXNWP was at the “subhealthy” level, with a membership function of 0.4643. This study found that habitat indicators (0.5715) were the key factors affecting the GXNWP health status, followed by service indicators (0.2856) and landscape indicators (0.1429). The HLS-AHP-FCE method provides a holistic health evaluation indicator system and diagnostic approach for rapidly developing wetland parks in the Pearl River Delta, China.
- 21 March 2021
- Published by Springer Nature in Wetlands
- Vol. 41 (4) , 1-16
Open AccessAn Effective Method for Wetland Park Health Assessment: a Case Study of the Guangdong Xinhui National Wetland Park in the Pearl River Delta, China
The Guangdong Xinhui National Wetland Park (GXNWP) in the Pearl River Delta is an important stopover for migratory birds in China and East Asia. Due to high levels of interference, high sensitivity and fragile environmental constraints, an efficient method to assess the health status of wetland parks such as the GXNWP is urgently needed for sustainable development. In this study, we proposed a habitat-landscape-service (HLS) conceptual model that can be used at the site scale to evaluate health status in terms of habitats, landscapes and services by considering the complex ecosystem of wetland parks. This HLS model included 28 evaluation indicators, and the indicator weights and health-grade divisions were based on expert scores using both the analytic hierarchy process (AHP) and fuzzy comprehension evaluation (FCE) methods. The results showed that the health status of the GXNWP was at the “subhealthy” level, with a membership function of 0.4643. This study found that habitat indicators (0.5715) were the key factors affecting the GXNWP health status, followed by service indicators (0.2856) and landscape indicators (0.1429). The HLS-AHP-FCE method provides a holistic health evaluation indicator system and diagnostic approach for rapidly developing wetland parks in the Pearl River Delta, China.